Evidence map›Paper›PMID 40045898›Full record

ArticleInfluenza and other respiratory viruses2025

Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study.

Bronke Boudewijns, Saverio Caini, Marco Del Riccio, Marta C Nunes, Sandra S Chaves, Melissa K Andrew, Justin R Ortiz, Oana Săndulescu, Joseph S Bresee, Elena Burtseva and 15 more

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Bronke BoudewijnsNetherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.ORCID 0000-0002-7214-4586
Saverio CainiNetherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.
Marco Del RiccioNetherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.ORCID 0000-0002-2742-0297
Marta C NunesCenter of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon (HCL) and Centre International de Recherche en Infectiologie (CIRI), Équipe Santé Publique, Épidémiologie et Écologie Évolutive des Maladies Infectieuses (PHE3ID), Inserm U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0003-3788-878X
Sandra S ChavesFoundation for Influenza Epidemiology, Fondation de France, Paris, France.
Melissa K AndrewDepartment of Medicine, Dalhousie University, Halifax, Canada.
Justin R OrtizCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Oana SăndulescuDepartment of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.ORCID 0000-0002-2586-4070
Joseph S BreseeTask Force for Global Health, Decatur, Georgia, USA.
Elena BurtsevaGamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russian Federation, Moscow, Russia.
Daouda CoulibalyEpidémiologie - Santé Publique, Institut National d'Hygiène Publique (INHP), Abidjan, Côte d'Ivoire.
Daria M DanilenkoSmorodintsev Research Institute of Influenza, St. Petersburg, Russia.
Kirill StolyarovSmorodintsev Research Institute of Influenza, St. Petersburg, Russia.
Anca C DrăgănescuDepartment of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Mine Durusu TanrioverHacettepe University Vaccine Institute, Ankara, Türkiye.
Heloisa I G GiamberardinoEpidemiology and Infection Control/Immunization Department, Pequeno Principe Hospital, Curitiba, Brazil.
Parvaiz A KoulSheri Kashmir Institute of Medical Sciences, Srinagar, India.
F Xavier Lopez-LabradorVirology Laboratory, FISABIO-Public Health, Generalitat Valenciana, Valencia, Spain.ORCID 0000-0002-9403-8258
Shelly A McNeilDepartment of Medicine, Dalhousie University, Halifax, Canada.
Ainara Mira-IglesiasCIBERESP Network Center for Epidemiology and Public Health, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-6371-8229
Alejandro Orrico-SanchezCIBERESP Network Center for Epidemiology and Public Health, Instituto de Salud Carlos III, Madrid, Spain.
Nancy A OtienoKenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Jorim AyugiKenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Sonia M RaboniMolecular Biology/Microbiology Research Laboratory, Universidade Federal Do Paraná, Curitiba, Brazil.ORCID 0000-0001-7907-7585
Peter SpreeuwenbergNetherlands Institute for Health Services Research (Nivel), Utrecht, the Netherlands.

Funding

Foundation for Influenza Epidemiology
6 · The paper itself

Abstract

backgroundThis study aimed to establish a Severity Scale for influenza and other acute respiratory infections (ARI), requiring hospitalization, for surveillance and research purposes (the SevScale). Such a scale could aid the interpretation of data gathered from disparate settings. This could facilitate pooled analyses linking viral genetic sequencing data to clinical severity, bringing insights to inform influenza surveillance and the vaccine strain selection process.

methodsWe used a subset of data from the Global Influenza Hospital Surveillance Network database, including data from different geographical areas and income levels. To quantify the underlying concept of severity, an item response model was developed using 16 indicators of severity related to the hospital stay. Each patient in the dataset was assigned a Severity Score and a Severity Category (low, medium, or high severity). Finally, we compared the model scores across different subgroups.

resultsData from 9 countries were included, covering between 4 and 11 seasons from 2012 to 2022, with a total of 96,190 ARI hospitalizations. Not for all severity indicators data were available for all included seasons. Subgroups with a high percentage of patients in the high Severity Category included influenza A(H1N1)pdm09, age ≥ 50, lower-middle income countries, and admission since the start of the COVID-19 pandemic.

conclusionsThe initial model successfully highlighted severity disparities across patient subgroups. Repeating this exercise with new, more complete data would allow recalibration and validation of the current model. The SevScale proved to be a promising method to define severity for influenza vaccine strain selection, surveillance, and research.

Indexed as

HospitalizationInfluenza, HumanRespiratory Tract InfectionsSeverity of Illness IndexAdolescentAdultAgedChildChild, PreschoolEpidemiological MonitoringFemaleGenome, ViralGlobal HealthHumansInfantInfluenza A Virus, H1N1 Subtypeacute respiratory infectioninfluenzaseverity

Identifiers

PMID40045898
PMCPMC11883289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.